ICON wins eLearning and Animation Awards for its FIRECREST Digital Solutions
06 Juillet 2017 - 11:00AM
Business Wire
FIRECREST training solutions used worldwide
by all top ten pharma in 1,100+ studies
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
its FIRECREST solutions have won gold and silver awards for
eLearning and digital animation. FIRECREST was awarded gold in the
International eLearning Awards (IELA) in the blended learning
category, and received a silver award for digital animation in the
Summit International Awards.
The annual International E-Learning Awards recognise excellence
in e-learning, mobile learning and blended learning in academia and
business. ICON’s Protocol Overview, which is part of the FIRECREST
Investigator Portal, was judged as the best blended learning
solution. Protocol Overview uses graphics, audio, animation and
other interactive tools to help investigators and site staff to
quickly process, retain and apply study-specific information to
clinical trials. It enables self-paced access to relevant
information, accommodating differing levels of knowledge and
experience of investigators and other site staff. Protocol Overview
has been implemented by the industry’s top ten pharma companies in
over 1,100 Ph I-IV studies in over 70 countries.
The annual Summit International Awards recognise excellence and
creativity in marketing communications. ICON’s hyperreal, 3D
animated video showcased a variety of creative design techniques
that educate study personnel on disease pathology and the
investigational product’s mechanism of action.
Commenting on both awards, ICON’s VP FIRECREST, Mark Connolly
said: “We are delighted to win such prestigious awards and to be
recognized once again for our innovative training and study
management solutions. Our FIRECREST solutions bring together
in-depth clinical research expertise with industry leading
instructional design, graphic and multimedia capabilities to
deliver a truly engaging experience for sponsors, study teams,
sites and patients. Our customers are benefiting from reduced
training & compliance costs, increased consistency in trial
execution, and reductions in preventable errors and protocol
deviations.”
To learn more about ICON’s FIRECREST suite of solutions, visit
www.iconplc.com/firecrest
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 87 locations in 38 countries and has approximately
12,300 employees.
Further information is available at www.iconplc.com
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170706005457/en/
ICON Media ContactCamille FrederixWeber Shandwick+44 (0)
207 067 0272cfrederix@webershandwick.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024